277MO SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2- metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study

Authors :: Aditya Bardia
A-L. Bauchet
Vasiliki Pelekanou
Marina Celanovic
N. Ternes
Sarat Chandarlapaty
J. Sang Lee
V. Boutet
Mario Campone
A. Protopopov
W. Dos-Santos Bele
E. Boitier
Hannah M. Linden
J. Ming
A. Gosselin
Simon Lord
Source :: Annals of Oncology. 31:S351
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Phase i ii
Oncology
business.industry
medicine
Cancer research
Estrogen receptor
Biomarker (medicine)
Hematology
medicine.disease
business
Metastatic breast cancer

Full Text Access

Tools